UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 27, 2007
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-21696 22-3106987
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
26 Landsdowne Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS
Extension of Terms of Employment Agreements for Named Executive Officers
ARIAD Pharmaceuticals, Inc. (the "Company") has entered into amendments of
employment agreements with the Company's named executive officers dated April
27, 2007 and May 1, 2007 to extend the terms of employment for such officers as
follows:
Term of Agreement Extended
Name and Title From To
(December 31 of each year)
- ------------------------------------------------------------------------------------------------------------------------------------
Harvey J. Berger, M.D. 2009 2011
Chairman and Chief Executive Officer
David L. Berstein, Esq. 2008 2010
Senior Vice President, Chief Patent Counsel
Timothy P. Clackson, Ph.D. 2008 2010
Senior Vice President, Chief Scientific Officer
Edward M. Fitzgerald
Senior Vice President, Finance and Corporate Operations, 2008 2010
Chief Financial Officer and Treasurer
John D. Iuliucci, Ph.D. 2008 2010
Senior Vice President, Chief Development Officer
The term of employment for each officer is thereafter subject to automatic
renewal for successive one-year terms (three-year terms in the case of Dr.
Berger) absent notice to the contrary by either party.
These extensions were approved by the Compensation Committee of the Board of
Directors and, for Dr. Berger's amendment, by the Board of Directors of the
Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARIAD Pharmaceuticals, Inc.
By: /s/ Edward M. Fitzgerald
-------------------------------------
Edward M. Fitzgerald
Senior Vice President, Finance and
Corporate Operations,
Chief Financial Officer
Date: May 2, 2007